Visit http://indiaer.blogspot.com/ for complete details Glenmark Pharma (Rating – Buy; Target Price – Rs346)
We expect the steady turnaround to continue and the topline to grow by 18% to Rs7bn.
The EBIDTA margin is expected to improve by 100bps to 27.5%.
We also expect the adjusted PAT to grow by 27.7% on a YoY basis to Rs1bn.
No comments:
Post a Comment